Publications of Tanya Dogra

Pelz, L.; Rüdiger, D.; Dogra, T.; Alnaji, F. G.; Genzel, Y.; Brooke, C. B.; Kupke, S. Y.; Reichl, U.: Semi-continuous propagation of influenza A virus and its defective interfering particles: analyzing the dynamic competition to select candidates for antiviral therapy. Journal of Virology 95 (24), e01174-21 (2021)

Hein, M.; Dogra, T.; Arora , P.; Rand , U.; Genzel, Y.; Cattaneo, M.; Winkler, M.; Cicin-Sain, L.; Bruder, D.; Schughart, K. et al.; Pöhlmann, S.; Kupke, S. Y.; Reichl, U.: Influenza A Virus-Derived Defective Interfering Particles for Antiviral Treatment. 27th ESACT Meeting, Lisbon (Portugal) (2022)

Pelz, L.; Rüdiger, D.; Dogra, T.; Alnaji, F.G.; Genzel, Y.; Brooke, C.B.; Kupke, S. Y.; Reichl, U.: Long-Term Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing Dynamic Competition to Select Antiviral Candidates. Vaccine Technology VIII, Sitges (Spain) (2022)

Pelz, L.; Rüdiger, D.; Dogra, T.; Alnaji, F. G.; Genzel, Y.; Brooke, C. B.; Kupke, S. Y.; Reichl, U.: Semi-Continuous propagation of Influenza A virus and its defective interfering particles: Analyzing the dynamic competition to select antiviral candidates. 27th ESACT Meeting, Lisbon (Portugal) (2022)

Dogra, T.; Pelz, L.; Marc, H.; Rüdiger, D.; Boehme, J.; Bruder, D.; Kupke, S. Y.; Reichl, U.: Reverse genetics for Influenza A virus to generate genetically engineered defective interfering particles for antiviral treatment and vaccination. 27th ESACT Meeting, Lisbon (Portugal) (2022)

Pelz, L.; Rüdiger, D.; Dogra, T.; Alnaji, F.G.; Genzel, Y.; Brooke, C.B.; Kupke, S. Y.; Reichl, U.: Long-Term Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing Dynamic Competition to Select Antiviral Candidates. Vaccine Technology VIII, Sitges (Spain) (2022)

Pelz, L.; Rüdiger, D.; Dogra, T.; Alnaji, F. G.; Genzel, Y.; Brooke, C. B.; Kupke, S. Y.; Reichl, U.: Semi-Continuous propagation of Influenza A virus and its defective interfering particles: Analyzing the dynamic competition to select antiviral candidates. 27th ESACT Meeting, Lisbon (Portugal) (2022)